| human | Q5 |
| P496 | ORCID iD | 0000-0002-0991-4381 |
| P735 | given name | ??? | Q18201513 |
| ??? | Q18201513 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q38424625 | Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE). |
| Q35739079 | Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus. |
| Q40664631 | Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients |
| Q28661353 | Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients |
| Q57782781 | Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up |
| Q42979579 | Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. |
| Q40141454 | Evaluation the Architect EBV VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent immunoassays to assess EBV serostatus prior transplantation. |
| Q38918608 | Identifying patients infected with hepatitis B virus in sub-Saharan Africa: potential for misclassification |
| Q55223784 | Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe. |
| Q42995849 | Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis |
| Q43047910 | Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis |
| Q92794781 | Kinetics of hepatitis B core-related antigen and anti-hepatitis B core antibody and their association with serological response in HIV-hepatitis B co-infection |
| Q45359671 | Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients |
| Q42150097 | Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire |
| Q42223115 | Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications |
| Q45352842 | Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus. |
| Q43042539 | Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy |
| Q42233095 | Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV. |
| Q50562416 | Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. |
Search more.